DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Vancomycin Versus Ceftaroline in Patients With Infections Caused by MRSA That Are Susceptible to Ceftaroline

Information source: CPL Associates
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: MRSA Infection; Bacteremia; ABSSSI; Pneumonia

Phase: N/A

Status: Not yet recruiting

Sponsored by: CPL Associates

Official(s) and/or principal investigator(s):
Jerome J Schentag, Pharm.D., Principal Investigator, Affiliation: State University at Buffalo

Overall contact:
Jerome J Schentag, Pharm.D, Phone: 716-633-3330, Ext: 204, Email: jschentag@cplassociates.com


To compare the time to pathogen eradication, and the relationship to the time to clinical improvement, between ceftaroline and case-matched vancomycin treated controls in the treatment of adults with serious infections caused by Methicillin-Resistant Staphylococcus aureus (MRSA).

Clinical Details

Official title: A Case Series of Ceftaroline-treated Patients With Infections Caused by MRSA That Are Susceptible to Ceftaroline, Compared to Vancomycin-treated Patients

Study design: Observational Model: Case Control, Time Perspective: Retrospective

Primary outcome: Bacterial Eradication

Secondary outcome: Test of Cure


Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.


Inclusion Criteria: 1. A positive MRSA culture, resulting from a blood or properly obtained infection site

sample, with a vancomycin MIC 1. 5 - 4. 0 mcg/mL and ceftaroline MIC ≤1 mcg/mL.

2. The patient was treated adequately with ceftaroline or vancomycin. 3. A medical history, clinical signs and symptoms, and radiological findings consistent with infection such as pneumonia, skin and wound, intra-abdominal infection and bacteremia associated with one of those infection sites. Patients must have had a body temperature >38C [100. 4F] or <36. 1C [97F] or leukocytosis (blood leukocyte count >10,000 cells/mm3) or >10% bands, at baseline. In the case of pneumonia, chest radiographic examination that show a new or progressive infiltrate, consolidation, cavitation, or pleural effusion. Rales or dullness to percussion on physical examination of the chest, new onset of purulent sputum, or change in quantity or character of sputum. Wound redness, swelling, and/or purulence in the case of ABSSSI 4. There should be sufficient numbers of follow up cultures of the infection site and/or blood to determine whether the infecting pathogen was eradicated, and preferably the day on which the eradication occurred. Additional inclusion criteria for patients with pneumonia: 1. Suspected or confirmed acute bacterial pneumonia due to MRSA in one of the following subgroups: Community-acquired bacterial pneumonia (CABP) i. e. those cases acquired outside the hospital and being admitted to the hospital for treatment of their pneumonia; or Hospital-acquired bacterial pneumonia (HABP), i. e., pneumonia that occurs 72 hours or more after admission, which was not incubating at the time of admission; or Ventilator-associated bacterial pneumonia (VABP), i. e., pneumonia that arises more than 48 hours after endotracheal intubation and ventilation; or Health Care-associated bacterial pneumonia (HCABP), which includes patients admitted from a long term care facility. 2. Pulmonary infiltration consistent with the diagnosis of pneumonia (new or progressive infiltrates, consolidation, with or without the presence of pleural effusion) documented by chest X-ray or CT within 48 hours prior to enrollment. 3. Suitable respiratory specimen (sputum/endotracheal specimen or specimen from an invasive procedure) for culture and Gram stain, with Gram-positive pathogens as the predominant organism. Average of at least 10 Gram-positive organisms per oil-immersion field in 10 fields (actual or calculated, 100x objective). Additional inclusion criteria for patients with other infection sites: 1. In all cases of bacteremia linked to a site/source, the isolate species and susceptibility should match between blood and primary site. Typical non-pneumonia sites of infection will include complicated intra-abdominal (cIAI) and ABSSSI. 2. In contrast, bacteremic patients with IV catheter as the only source will require that the catheter was removed/replaced, and yet the patient remains culture positive for at least 24 hr after replacement of the catheter. Exclusion Criteria 1. Age <18 years 2. Pregnant or lactating women 3. Life expectancy <3 months from underlying disease 4. Infection with Mycobacterium tuberculosis 5. Organism is not available or is not tested locally for MIC to ceftaroline or vancomycin 6. Bacteremia determined to be catheter-related with no definitive evidence of a secondary source 7. Patient is on a prior antibiotic and shows clinical improvement or negative cultures before treatment of ceftaroline (or vancomycin for control patients).

Locations and Contacts

Jerome J Schentag, Pharm.D, Phone: 716-633-3330, Ext: 204, Email: jschentag@cplassociates.com

Erie County Medical Center, Buffalo, New York 14215, United States; Not yet recruiting
Joseph Paladino, Pharm.D., Phone: 716-633-3330, Ext: 202, Email: jpaladino@cplassociates.com
Joseph Paladino, Pharm.D., Principal Investigator
Additional Information

Starting date: December 2012
Last updated: November 7, 2012

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017